Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether ublituximab is safe and effective in
patients with relapsed or refractory B-cell lymphoma who were previously treated with
rituximab.